Transgene’s Phase II trial of viral-based vaccine TG4001 failed to meet its primary endpoint. Credit: Kitsawet Saethao via Shutterstock. Transgene’s stock has dropped after a Phase II trial of its ...
Trans­gene’s ther­a­peu­tic can­cer vac­cine can­di­date has failed a mid-stage test in cer­tain HPV-dri­ven can­cers, send­ing its shares down around 14% Mon­day … ...
Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to improve progression-free survival (PFS), the French biotech is ...